Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2018-05-29 AGM Information
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Communiqués de mise à disposition de documents / Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 95% confidence The document is a press release dated May 29, 2018, announcing the availability of preparatory documents for the upcoming Annual General Meeting (AGM) scheduled for June 19, 2018. The title explicitly mentions 'Modalités de mise à disposition et de consultation des documents préparatoires à l'Assemblée Générale Mixte' (Procedures for making available and consulting documents preparatory to the Combined General Meeting). Since the document itself is an announcement about the availability of AGM materials, and not the AGM presentation itself or the voting results, it fits best under the category related to shareholder meetings and voting information. The most specific category is 'AGM Information' (AGM-R) or potentially 'Proxy Solicitation & Information Statement' (PSI) as it relates to materials for the meeting. Given the focus on the 'Assemblée Générale' and the availability of preparatory documents, AGM-R is the primary fit, although it is an announcement *about* the AGM materials rather than the materials themselves. However, since the document is short (4375 chars) and primarily serves to inform shareholders about where to find the AGM documents, it strongly aligns with the context of shareholder meeting preparation. If the document were the actual presentation slides or minutes, AGM-R would be certain. As it is an announcement regarding the AGM, and AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', this announcement is directly related to that event. Given the options, AGM-R is the most relevant classification for a notice concerning the AGM documents.
2018-05-29 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 16, 2018, announcing a strategic research collaboration between Genomic Vision and the Children's Medical Research Institute (CMRI) regarding a telomere length assay. It details the purpose, scientific background, and quotes from executives. This type of announcement, which details a specific business development, partnership, or research milestone, is typically classified as a general regulatory announcement or press release that doesn't fit the more specific financial report categories (like 10-K, ER, or IR). Since it is not a formal financial report, a transcript, or a specific corporate action notice (like dividend or director dealing), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and press releases.
2018-05-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 16, 2018, announcing a strategic research collaboration between Genomic Vision and the Children's Medical Research Institute (CMRI) regarding telomere length studies for diagnostic test development. This type of announcement, detailing a new partnership, scientific development, and future product pipeline, is characteristic of corporate news releases intended for investors and the public. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it announces a significant business development and partnership, it falls best under a general corporate announcement category. Given the options, it is a general corporate communication that doesn't fit the highly specific categories like M&A (TAR), Financing (CAP), or Director Dealing (DIRS). It is most appropriately classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard announcements, or potentially Investor Presentation (IP) if it were structured as a presentation, but as a press release detailing a partnership, RNS is the most suitable fallback for significant corporate news that isn't explicitly defined elsewhere.
2018-05-16 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is an 'Information relative au nombre total de droits de vote et d'actions composant le capital social' (Information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and voting rights (Gross and Net) as of a specific date (30.04.2018). This content directly relates to the structure of the company's capital and voting rights, which is a specific type of regulatory disclosure. While it is a disclosure about capital structure, it is not a general capital raising announcement (CAP) or a major shareholding notification (MRQ) by an external party. It is a mandatory periodic disclosure regarding the total share capital and voting rights. This type of filing, which details the total number of shares and voting rights, is often categorized under general regulatory disclosures or specific capital structure updates. Given the options, it most closely aligns with a disclosure about the capital structure, but since it is a mandatory periodic report on the total capital/voting rights, and not a transaction (POS) or a change in major ownership (MRQ), it fits best under a general regulatory filing category if a more specific one isn't available. However, since it is a formal declaration about the total capital structure, it is a specific regulatory filing. Reviewing the definitions, none perfectly match 'Total Voting Rights Disclosure'. It is a regulatory filing (RNS) or potentially related to capital structure (CAP/SHA). Since it is a mandatory disclosure about the total number of shares and voting rights, it is a standard regulatory filing. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for specific, non-standard regulatory disclosures not covered by the other codes, although it is a very specific type of disclosure. If we consider 'SHA' (Share Issue/Capital Change), this document reports the *current state* of the capital, not an *issue* or *change* announcement, although it is related. Given the context of AMF regulation and capital structure reporting, RNS is the safest general classification for this specific periodic disclosure.
2018-05-07 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a press release dated May 2, 2018, announcing that Genomic Vision was invited to present its molecular combing technology at a Genopole seminar. It details the presentation content, includes quotes from management, and provides standard 'About Us' sections and contact information. This format is typical of an announcement regarding company activity, scientific presentation, or general corporate news that doesn't fit the strict definitions of financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, DIRS). Since it is a general announcement about participation in an industry event and scientific updates, and it is not a formal regulatory filing like a 10-K or a specific financial report, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for non-standard corporate communications, although it strongly resembles an Investor Presentation (IP) in content focus, it is structured as a press release announcing participation, not the presentation itself. Given the options, and its nature as a general corporate update/news release, RNS is the safest fallback, though IP is a close second if the content were the actual presentation slides. Since it is an announcement *about* presenting, RNS (Regulatory Filings/General Announcement) is selected.
2018-05-02 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 24, 2018, announcing that Genomic Vision was invited to present its technology at a Genopole seminar. It details the content of the presentation and includes standard sections like 'ABOUT GENOPOLE', 'ABOUT GENOMIC VISION', and 'CONTACTS'. This type of announcement, which communicates company news, participation in industry events, or general business updates outside of mandatory financial reporting (like 10-K or ER), typically falls under general Regulatory Filings (RNS) or potentially Investor Presentation (IP) if it were the presentation itself. Since this is an announcement *about* a presentation/seminar participation, and not a core financial report, it best fits the general regulatory announcement category. It is not a 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). It is not a DEF 14A (Remuneration) or DVA (Voting Results). It is a specific corporate update that doesn't fit the other specialized codes (like M&A, Capital Change, Director Dealing). Therefore, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate classification.
2018-05-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.